BackOnco-Innovations Overview

Onco-Innovations EBIT

Track Onco-Innovations's EBIT ($-12M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.03M
↓ 24.97% YoY

As of Jan 31, 2026

Annual EBIT (TTM)

-$11.72M

Trailing 12 months ending Jan 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Onco-Innovations (ONCO.CN) FAQ

The latest EBIT for ONCO.CN is $-12M as of January 2026. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Onco-Innovations's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, ONCO.CN currently prints $-12M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Onco-Innovations's growth, margins, and balance sheet.

A EBIT figure of $-12M for ONCO.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting ONCO.CN's EBIT ($-12M), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Onco-Innovations's EBIT against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.